Cargando…

Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy

The phenomenon of histological transformation has been widely reported in advanced non-small cell lung cancer (NSCLC) with EGFR mutations following the failure of EGFR-TKI treatment. Recent evidence suggests that similar histological changes can also occur in advanced NSCLC without driver gene mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Jiao, Ding, Xinjing, Ding, Jianghua, Wang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646212/ https://www.ncbi.nlm.nih.gov/pubmed/38022621 http://dx.doi.org/10.3389/fimmu.2023.1275957

Ejemplares similares

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
por: Wang, Zhi, et al.
Publicado: (2022)

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
por: Xia, Guohao, et al.
Publicado: (2023)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Transcriptional patterns reveal tumor histologic heterogeneity and immunotherapy response in lung adenocarcinoma
por: Jiao, Mengxue, et al.
Publicado: (2022)

Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy
por: Shao, Chuchu, et al.
Publicado: (2021)

Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
por: Fang, Pinhao, et al.
Publicado: (2022)

LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
por: Ding, Jianghua, et al.
Publicado: (2022)

Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC
por: Nikolakopoulou, Asimina, et al.
Publicado: (2022)

Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports
por: Lai, Lin, et al.
Publicado: (2021)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

DT-diaphorase activity in NSCLC and SCLC cell lines: a role for fos/jun regulation
por: Kepa, J K, et al.
Publicado: (1999)

Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report
por: Ding, Xinjing, et al.
Publicado: (2021)

Mechanism and strategies of immunotherapy resistance in colorectal cancer
por: Shan, Jiqi, et al.
Publicado: (2022)

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
por: Chen, Shen, et al.
Publicado: (2019)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
por: Li, Huihui, et al.
Publicado: (2023)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
por: Paul, Sourav, et al.
Publicado: (2017)

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
por: Wang, Ding-Kang, et al.
Publicado: (2021)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies
por: Nardone, Valerio, et al.
Publicado: (2018)

Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Schmiechen, Zoe C., et al.
Publicado: (2021)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

Effect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis
por: Yoo, Seung Soo, et al.
Publicado: (2020)

Next-Generation Sequencing in Lung Cancer Patients: A Comparative Approach in NSCLC and SCLC Mutational Landscapes
por: Pop-Bica, Cecilia, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC
por: Fu, Yu, et al.
Publicado: (2023)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
por: Wang, Shuyue, et al.
Publicado: (2021)

Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022)

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
por: Shi, Tao, et al.
Publicado: (2023)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
por: Chen, Xin, et al.
Publicado: (2019)

Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma
por: Ding, Xinjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1sbia43iq5slsbdf6ql98oespk